STING agonists have promising biological activity and show excellent synergistic antitumor effects in combination with other cancer therapies such as radiotherapy, chemotherapy, or immune therapies, as has been proven in preclinical studies and some clinical trials [79]. The gene discussed is STING1; the disease is cancer.